Homoharringtonine (HHT) plus cytarabine (Ara-C) for chronic myeloid leukemia in accelerated phase (CML-AP).

被引：0
|
作者：
Maloisel, F
De Sarrazin, A
Fohrer, C
Rousselot, P
Maisonneuve, H
Lucas, P
Campos, F
Dufour, P
Bergerat, JP
机构：
[1] Hop Civil, Dept Hematol & Oncol, Strasbourg, France
[2] Hop St Louis, Paris, France
[3] CHD, La Roche Sur Yon, France
[4] Polyclin Les Bleuets, Reims, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4778
引用
收藏
页码：262B / 262B
页数：1
相关论文
共 50 条
  • [21] Homoharringtonine is effective in accelerated phase of chronic myeloid leukemia.
    Chen, CI
    MacKinnon, J
    Yee, K
    Kamel-Reid, S
    Crump, M
    Keating, A
    BLOOD, 1998, 92 (10) : 242B - 242B
  • [22] Comparison of HLA-identical sibling bone marrow transplants (BMT) versus interferon plus cytarabine (IFN/Ara-C) for chronic myelogenous leukemia (CML) in chronic phase (CP).
    Guilhot, F
    Sobocinski, K
    Guilhot, J
    Zhang, M
    Giralt, S
    Harousseau, JL
    Michallet, M
    Maloisel, F
    Blaise, D
    Guerci, A
    Horowitz, M
    BLOOD, 2000, 96 (11) : 545A - 545A
  • [23] Results of the clinical. use of the combination regiment of homoharringtonine (HHT) and cytarabine in the management of late chronic phase and accelerated phase chronic myelogenous leukemia.
    De Sarrazin, A
    Fohrer, C
    Madelaine-Chambrin, I
    Dumont, J
    Najman, A
    Vehkkof, J
    Briere, J
    Solal-Celigny, P
    Decaudin, D
    Boulanger, E
    Guillemin, F
    Legros, L
    Larghero, J
    Robin, JP
    Maloisel, F
    Rousselot, P
    BLOOD, 2001, 98 (11) : 350A - 350A
  • [24] Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
    Heo, Sook-Kyoung
    Noh, Eui-Kyu
    Yu, Ho-Min
    Kim, Do Kyoung
    Seo, Hye Jin
    Lee, Yoo Jin
    Cheon, Jaekyung
    Koh, Su Jin
    Min, Young Joo
    Choi, Yunsuk
    Jo, Jae-Cheol
    BMC CANCER, 2020, 20 (01)
  • [25] Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
    Sook-Kyoung Heo
    Eui-Kyu Noh
    Ho-Min Yu
    Do Kyoung Kim
    Hye Jin Seo
    Yoo Jin Lee
    Jaekyung Cheon
    Su Jin Koh
    Young Joo Min
    Yunsuk Choi
    Jae-Cheol Jo
    BMC Cancer, 20
  • [26] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Le Coutre, P. D.
    Giles, F.
    Hochhaus, A.
    Apperley, J. F.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Imatinib plus Ara-C (IMAC) vs. imatinib plus etoposide (IMETO) for the treatment of accelerated (AP) and blastic (BP) phase chronic myeloid leukemia (CML) Ph+. A randomized phase II clinical trial. Preliminary report of Mexican Cooperative Leukemia Group (GRUMELA).
    Ceballos, EC
    Torres, MA
    Hernandez, MC
    Viveros, PV
    Monroy, RH
    Lobato, EM
    Labardini, JM
    BLOOD, 2003, 102 (11) : 321B - 321B
  • [28] Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study
    le Coutre, P.
    Giles, F. J.
    Apperley, J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Rosti, G.
    Cortes, J. E.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis
    Hochhaus, Andreas
    Apperley, Jane F.
    Ossenkoppele, Gert
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    Cortes, Jorge
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 1108 - 1109
  • [30] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Hochhaus, A.
    Giles, F.
    Apperely, J.
    Ossenkoppele, G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 256 - 256
12345